Trastuzumab Stable Cell Line - CHO-K1

CHO-K1 is a comprehensively characterized mammalian cell line originally derived from the ovary of an adult Chinese hamster (Cricetulus griseus). Growing typically as an adherent epithelial-like monolayer—but highly adaptable to high-density, serum-free suspension culture—CHO-K1 is the undisputed industry standard for the biomanufacturing of complex recombinant proteins due to its robust growth kinetics and capacity for human-compatible post-translational modifications, particularly glycosylation. The Trastuzumab Stable Cell Line - CHO-K1 advances this foundational bioprocessing model through the stable genetic integration of the sequences encoding the heavy and light chains of Trastuzumab. Trastuzumab is a pioneering humanized monoclonal antibody (IgG1 kappa) that specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2), a receptor tyrosine kinase frequently overexpressed in aggressive breast and gastric cancers. This precise genetic engineering ensures the constitutive, high-titer expression and proper assembly of the functional antibody. The engineered cells strictly maintain their native metabolic stability, robust proliferative capacity, and scalability, providing a highly reliable and authentic platform for antibody production.

The constitutive expression of functional, full-length Trastuzumab transforms this CHO-K1 cell line into an indispensable asset for biopharmaceutical process development, pharmacological analytics, and targeted oncology research. In biomanufacturing environments, this stable cell line serves as a premier model for optimizing upstream bioprocessing parameters—such as defined media formulation, advanced feed strategies, and large-scale bioreactor adaptation—to maximize monoclonal antibody (mAb) yield and structural consistency. It provides a continuous, reliable source of recombinant Trastuzumab for downstream purification optimization and analytical characterization. Beyond process development, the purified antibody produced by these cells is highly valuable for conducting rigorous in vitro functional assays, including the evaluation of Antibody-Dependent Cellular Cytotoxicity (ADCC) against HER2-positive breast and gastric carcinoma lines (such as SK-BR-3 or NCI-N87). Furthermore, this cell line is extensively utilized in the preclinical evaluation of next-generation biosimilars and biobetters, serving as a critical reference platform to assess target binding affinity, pharmacokinetic profiles, and anti-proliferative efficacy in the context of HER2-driven malignancies.